These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1121 related items for PubMed ID: 16120030

  • 21. Comparison between a multiple daily insulin injection regimen (basal once-daily glargine plus mealtime lispro) and continuous subcutaneous insulin infusion (lispro) using continuous glucose monitoring in metabolically optimized type 1 diabetes patients: A randomized open-labelled parallel study.
    Ruiz-de-Adana MS, Dominguez-Lopez ME, Gonzalez-Molero I, Machado A, Martin V, Cardona I, de-la-Higuera M, Tapia MJ, Soriguer F, Anarte MT, Rojo-Martínez G.
    Med Clin (Barc); 2016 Mar 18; 146(6):239-46. PubMed ID: 26656958
    [Abstract] [Full Text] [Related]

  • 22. Does the timing of insulin pump therapy initiation after type 1 diabetes onset have an impact on glycemic control?
    Shalitin S, Lahav-Ritte T, Lebenthal Y, Devries L, Phillip M.
    Diabetes Technol Ther; 2012 May 18; 14(5):389-97. PubMed ID: 22283639
    [Abstract] [Full Text] [Related]

  • 23. Does treatment with an insulin pump improve glycaemic control in children and adolescents with type 1 diabetes? A retrospective case-control study.
    Brorsson AL, Viklund G, Örtqvist E, Lindholm Olinder A.
    Pediatr Diabetes; 2015 Nov 18; 16(7):546-53. PubMed ID: 25327782
    [Abstract] [Full Text] [Related]

  • 24. The impact of continuous subcutaneous insulin infusion and multiple daily injections of insulin on glucose variability in older adults with type 2 diabetes.
    Johnson SL, McEwen LN, Newton CA, Martin CL, Raskin P, Halter JB, Herman WH.
    J Diabetes Complications; 2011 Nov 18; 25(4):211-5. PubMed ID: 21062674
    [Abstract] [Full Text] [Related]

  • 25. Long-term body weight trajectories and metabolic control in type 1 diabetes patients on insulin pump or multiple daily injections: A 10-year retrospective controlled study.
    Alderisio A, Bozzetto L, Franco L, Riccardi G, Rivellese AA, Annuzzi G.
    Nutr Metab Cardiovasc Dis; 2019 Oct 18; 29(10):1110-1117. PubMed ID: 31371264
    [Abstract] [Full Text] [Related]

  • 26. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis.
    Yeh HC, Brown TT, Maruthur N, Ranasinghe P, Berger Z, Suh YD, Wilson LM, Haberl EB, Brick J, Bass EB, Golden SH.
    Ann Intern Med; 2012 Sep 04; 157(5):336-47. PubMed ID: 22777524
    [Abstract] [Full Text] [Related]

  • 27. Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in type 1 diabetic patients previously treated with CSII.
    Hirsch IB, Bode BW, Garg S, Lane WS, Sussman A, Hu P, Santiago OM, Kolaczynski JW, Insulin Aspart CSII/MDI Comparison Study Group.
    Diabetes Care; 2005 Mar 04; 28(3):533-8. PubMed ID: 15735183
    [Abstract] [Full Text] [Related]

  • 28. Switch to multiple daily injections with insulin glargine and insulin lispro from continuous subcutaneous insulin infusion with insulin lispro: a randomized, open-label study using a continuous glucose monitoring system.
    Bode BW, Steed RD, Schleusener DS, Strange P.
    Endocr Pract; 2005 Mar 04; 11(3):157-64. PubMed ID: 16239201
    [Abstract] [Full Text] [Related]

  • 29. Continuous glucose monitoring in children with type 1 diabetes: before and after insulin pump therapy.
    Heptulla RA, Allen HF, Gross TM, Reiter EO.
    Pediatr Diabetes; 2004 Mar 04; 5(1):10-5. PubMed ID: 15043684
    [Abstract] [Full Text] [Related]

  • 30. Treatment satisfaction and glycemic control in young Type 1 diabetic patients in transition from pediatric health care: CSII versus MDI.
    Maiorino MI, Bellastella G, Petrizzo M, Improta MR, Brancario C, Castaldo F, Olita L, Giugliano D.
    Endocrine; 2014 Jun 04; 46(2):256-62. PubMed ID: 24078410
    [Abstract] [Full Text] [Related]

  • 31. Continuous subcutaneous insulin infusion. A new way to lower risk of severe hypoglycemia, improve metabolic control, and enhance coping in adolescents with type 1 diabetes.
    Boland EA, Grey M, Oesterle A, Fredrickson L, Tamborlane WV.
    Diabetes Care; 1999 Nov 04; 22(11):1779-84. PubMed ID: 10546007
    [Abstract] [Full Text] [Related]

  • 32. A comparison of multiple daily insulin therapy with continuous subcutaneous insulin infusion therapy in adolescents with type 1 diabetes mellitus: a single-center experience from Turkey.
    Abaci A, Atas A, Unuvar T, Demir K, Bober E, Büyükgebiz A.
    J Pediatr Endocrinol Metab; 2009 Jun 04; 22(6):539-45. PubMed ID: 19694201
    [Abstract] [Full Text] [Related]

  • 33. Continuous subcutaneous insulin infusion versus multiple daily injection therapy in pregnant women with type 1 diabetes.
    Gong Y, Wei T, Liu Y, Wang J, Yan J, Yang D, Luo S, Weng J, Zheng X.
    J Diabetes; 2024 May 04; 16(5):e13558. PubMed ID: 38664886
    [Abstract] [Full Text] [Related]

  • 34. Real-time continuous glucose monitoring or continuous subcutaneous insulin infusion, what goes first?: results of a pilot study.
    Moreno-Fernandez J, Gomez FJ, Gazquez M, Pedroche M, García-Manzanares A, Tenias JM, Benito P, Gomez IR.
    Diabetes Technol Ther; 2013 Jul 04; 15(7):596-600. PubMed ID: 23631604
    [Abstract] [Full Text] [Related]

  • 35. A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with type 2 diabetes.
    Herman WH, Ilag LL, Johnson SL, Martin CL, Sinding J, Al Harthi A, Plunkett CD, LaPorte FB, Burke R, Brown MB, Halter JB, Raskin P.
    Diabetes Care; 2005 Jul 04; 28(7):1568-73. PubMed ID: 15983302
    [Abstract] [Full Text] [Related]

  • 36. Long-term metabolic effects of continuous subcutaneous insulin infusion therapy in type 1 diabetes.
    Cohen ND, Hong ES, Van Drie C, Balkau B, Shaw J.
    Diabetes Technol Ther; 2013 Jul 04; 15(7):544-9. PubMed ID: 23617252
    [Abstract] [Full Text] [Related]

  • 37. Long-Term Effectiveness of Continuous Subcutaneous Insulin Infusion in the Prevention of Hypoglycemia in Adults with Type 1 Diabetes.
    Summers JC, Briganti EM, Fitzgerald ZA, Lambers LNJ, Cohen ND.
    Diabetes Technol Ther; 2019 Aug 04; 21(8):423-429. PubMed ID: 31180239
    [Abstract] [Full Text] [Related]

  • 38. Fear of hypoglycemia in type 1 diabetes managed by continuous subcutaneous insulin infusion: is it associated with poor glycemic control?
    Nixon R, Pickup JC.
    Diabetes Technol Ther; 2011 Feb 04; 13(2):93-8. PubMed ID: 21284474
    [Abstract] [Full Text] [Related]

  • 39. Continuous subcutaneous insulin infusion versus multiple daily injection regimens in children and young people at diagnosis of type 1 diabetes: pragmatic randomised controlled trial and economic evaluation.
    Blair JC, McKay A, Ridyard C, Thornborough K, Bedson E, Peak M, Didi M, Annan F, Gregory JW, Hughes DA, Gamble C, SCIPI investigators.
    BMJ; 2019 Apr 03; 365():l1226. PubMed ID: 30944112
    [Abstract] [Full Text] [Related]

  • 40. Intensive insulin therapy combined with metformin is associated with reduction in both glucose variability and nocturnal hypoglycaemia in patients with type 2 diabetes.
    Zhang Y, Zhao Z, Wang S, Zhu W, Jiang Y, Sun S, Chen C, Wang K, Mu L, Cao J, Zhou Y, Gu W, Hong J, Wang W, Ning G.
    Diabetes Metab Res Rev; 2017 Oct 03; 33(7):. PubMed ID: 28609547
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 57.